Tag: Yale School of Medicine

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

-Company expects to initiate Phase 2 study in 2H 2025- SAN DIEGO, July 30, 2025 /PRNewswire/ -- EuMentis Therapeutics, Inc., ("EuMentis"), a clinical-stage drug development company...

NEW HAVEN, Conn., July 8, 2025 /PRNewswire-HISPANIC PR WIRE/ -- Yale School of Medicine (YSM) was awarded a $27.7 million grant from Aligning Research...

NEW HAVEN, Conn., July 8, 2025 /PRNewswire/ -- Yale School of Medicine (YSM) was awarded a $27.7 million grant from Aligning Research to Impact...

Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) in Tel Aviv, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable patient enrollment at TASMC, a leading clinical site in Israel, prior to commencing this first-in-human trial at the site.

NEW HAVEN, Conn., June 20, 2025 /PRNewswire-HISPANIC PR WIRE/ -- Yale School of Medicine (YSM) announces the launch of the Yale Biomedical Imaging Institute, a...

NEW HAVEN, Conn., June 20, 2025 /PRNewswire/ -- Yale School of Medicine (YSM) announces the launch of the Yale Biomedical Imaging Institute, a cross-disciplinary hub that...